The vice president of finance at Heat Biologics Inc., a Durham-based biotechnology company, will retire at the end of March and be replaced by a new executive at the company, according to a filing Tuesday with the Securities and Exchange Commission.

Ann A. Rosar will retire on March 31. But she will remain with the company through the end of the year as a consultant and will be paid her current salary in April. After that, she will be paid an hourly rate for consulting services.

She is being replaced, effective April 1, by Robert J. Jakobs, who joined the company on March 4 as controller.

Jakobs, 64, most recently served as vice president of accounting and finance of Anutra Medical Inc. from 2014 to February 2019. Prior to that, he served as an independent chief financial officer/controller partner at Rankin McKenzie Partners from 2012 through 2014.

He also served as senior director of accounting and finance at Icagen Inc. from 1996 through 2012. In addition, Jakobs served as corporate controller of Sphinx Pharmaceuticals, a publicly traded biotechnology company that was acquired by Eli Lilly, and worked in various accounting positions in the chemical and equipment manufacturing companies.

He will receive a base salary of $220,000 and be eligible to receive a bonus of up to 20 percent of his salary.

Heat Biologics is developing drugs designed to activate a patient’s immune system against cancer. It was founded in 2008 with the mission to change how cancer is treated through therapies that harness a patient’s immune system.

Heat Bio’s stock closed Tuesday at $1.25, up 3 cents.